Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Dillon

Showing results (81-90 of 176) with videos related to

Pageof 18
Sort By:
The Lancet Regional Health. Europe|November 14, 2025
Estimating incidence rates of primary infection and reinfection with hepatitis C virus among people who inject drugs in Scotland: a model-based analysis of repeated cross-sectional survey dataScott A McDonald, Norah Palmateer, Andrew McAuley, et al.
Frontline Gastroenterology|September 2, 2022
Identification of liver disease: why and howIain Macpherson, Kushala W M Abeysekera, Rebecca Harris, et al.
Journal of Viral Hepatitis|November 14, 2018
High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programmeJasmine Schulkind, Brian Stephens, Farsana Ahmad, et al.
BMJ Open|August 11, 2019
Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment-ADVANCE HCV protocol studySarah K Inglis, Lewis Jz Beer, Christopher Byrne, et al.
The Lancet. Gastroenterology & Hepatology|June 12, 2020
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trialAndrew Radley, Marijn de Bruin, Sarah K Inglis, et al.
British Journal of Health Psychology|July 12, 2025
Post-treatment life-trajectories among people who inject drugs who completed hepatitis C treatment with direct acting antivirals: A thematic analysisGabriele Vojt, Lawrie Elliott, Hannah Family, et al.
European Journal of Gastroenterology & Hepatology|September 24, 2009
Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage studyScott A McDonald, Sharon J Hutchinson, Sheila M Bird, et al.
Alimentary Pharmacology & Therapeutics|December 8, 2021
Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, ScotlandChristopher J Byrne, Lewis Beer, Sarah K Inglis, et al.
Journal of Hepatology|February 11, 2014
Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation modelHamish Innes, David Goldberg, Geoffrey Dusheiko, et al.
BMJ Open Gastroenterology|March 23, 2022
Predicting 1-year mortality among patients with decompensated cirrhosis: results of a multicentre evaluation of the Bristol Prognostic ScoreSarah Pauline Bowers, Kathleen Clare, Louise Hagerty, et al.
Pageof 18

Showing results (81-90 of 176) with videos related to

Sort By:
Pageof 18
The Lancet Regional Health. Europe|November 14, 2025
Estimating incidence rates of primary infection and reinfection with hepatitis C virus among people who inject drugs in Scotland: a model-based analysis of repeated cross-sectional survey dataScott A McDonald, Norah Palmateer, Andrew McAuley, et al.
Frontline Gastroenterology|September 2, 2022
Identification of liver disease: why and howIain Macpherson, Kushala W M Abeysekera, Rebecca Harris, et al.
Journal of Viral Hepatitis|November 14, 2018
High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programmeJasmine Schulkind, Brian Stephens, Farsana Ahmad, et al.
BMJ Open|August 11, 2019
Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment-ADVANCE HCV protocol studySarah K Inglis, Lewis Jz Beer, Christopher Byrne, et al.
The Lancet. Gastroenterology & Hepatology|June 12, 2020
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trialAndrew Radley, Marijn de Bruin, Sarah K Inglis, et al.
British Journal of Health Psychology|July 12, 2025
Post-treatment life-trajectories among people who inject drugs who completed hepatitis C treatment with direct acting antivirals: A thematic analysisGabriele Vojt, Lawrie Elliott, Hannah Family, et al.
European Journal of Gastroenterology & Hepatology|September 24, 2009
Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage studyScott A McDonald, Sharon J Hutchinson, Sheila M Bird, et al.
Alimentary Pharmacology & Therapeutics|December 8, 2021
Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, ScotlandChristopher J Byrne, Lewis Beer, Sarah K Inglis, et al.
Journal of Hepatology|February 11, 2014
Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation modelHamish Innes, David Goldberg, Geoffrey Dusheiko, et al.
BMJ Open Gastroenterology|March 23, 2022
Predicting 1-year mortality among patients with decompensated cirrhosis: results of a multicentre evaluation of the Bristol Prognostic ScoreSarah Pauline Bowers, Kathleen Clare, Louise Hagerty, et al.
Pageof 18